期刊文献+

(S)-卡巴拉汀D-(+)-DTTA盐的合成与晶体结构 被引量:1

Synthesis and crystal structure of (S)-rivastigmine D-(+)-DTTA
下载PDF
导出
摘要 标题化合物由3-(1-二甲氨基乙基)苯酚与N-乙基-N-甲基氨基甲酰氯反应合成卡巴拉汀游离碱,再与(+)-O,O′-二对甲基苯甲酰-D-酒石酸(D-(+)-DTTA)成非对映体盐制得。它的晶体结构已通过单晶X-射线衍射测试得到确定。通过对3477个可以观察到的独立衍射点[I>2σ(I)]的测试,结果表明:该晶体属于斜方晶系,P21212空间群,a=14.6084(7),b=30.7876(14),c=7.5442(3),α=90,β=90,γ=90,V=3393.1(3)3,Z=2,Dc=1.246mg/m3,μ=0.092mm-1,F(000)=1352,R=0.0529,wR=0.1459。 The compound ( S)-rivastigmine D- ( + )-DTTA ( [ C34 H40N2O10], Mr = 636.27) was synthesized by the reaction of 3- ( 1-dimethylaminoethyl )-phenol with N-ethyl-N-methylcar- bamoylchlofide, followed by preparation of the diastereoisomeric salt with ( + )-O, O'-di-(p-toluoyl)-D-tartaric acid (D-( + )- DTTA). Its crystal structure was determined by the single-crystal X-ray diffraction method. The crystal was of an orthorhombic system,with a space group of P21 21 2 having the following parameters: a = 14.608 4 (7)A, b = 30.787 6 (14)A, c = 7.544 2(3)A, α = 90,β = 90, γ = 90, V = 339 3. 1(3)A^3, Z = 2,Dc = 1.246 Mg/m^3, μ =0.092 mm^-1, F(000) = 1 352,R = 0.052 9 and wR = 0.1459.
机构地区 暨南大学药学院
出处 《化学试剂》 CAS CSCD 北大核心 2009年第7期511-514,共4页 Chemical Reagents
基金 广州市科技局科技计划项目(2005Z3-E5121)
关键词 卡巴拉汀 合成 晶体结构 rivastigmine zynthesis crystal atrueture
  • 相关文献

参考文献9

  • 1BOLOGNESI M L,BARTOL[N] M,CAVAULLI A,et al.Synthesis,and biological evaluation of conformationally restricted rivastigmine analogues[J].J.Med.Chem.,2004,47(24):5 945-5 952.
  • 2肖增平,吉爱国.老年痴呆的发病机制及治疗的研究进展[J].中国老年学杂志,2008,28(1):95-97. 被引量:53
  • 3GOTTWALD M D,ROZANSKI R I.Rivastigmine,a brain-region selective acetylcholinesterase inhibitor for treatingAlzheimer's disease:review and current status[J].Expen Opin.Invest.Drug.,1999,8(10):1 673-1 682.
  • 4ENZ A.Preparation and use of phenylcarbamate cholinergic agonists as central nervous agcots:DE,3 805 744[P].1988-09-15.
  • 5AMSTUTZ R,ENZ A,MARZI M,et al.Cyclic phenyl carbamates and their action on acetylcholinesterase[J].Helv.Chim.Acta.,1990,73(3):739-753.
  • 6FIELDHOUSE R.Stereoselective process for the preparation of tertiary amines attached to a secondary carbon center using a chiral transition metal transfer hydrogenation catalyst:WO,2 005 058 804[P].2005-06-30.
  • 7GEROTHANASSIS I P,VAKKA C,TROGANIS A.17ONMR studies of the solvation state of cis/trans isomers of amides and model protected peptides[J].J.Magn.Resort.Ser.B.,1996,111(3):220-229.
  • 8SILVA J B P,SRIVASTAVA R M.Conformational preferences of N-ethyl,N-methylacetamide and their correlations with the NMR chemical shifts:a theoretical study[J].J.Mol.Strua.,2004,682,145-151.
  • 9BAR O P,MILLARD B,HAREL M,et al.Kinetic and structural studies on the interction of chohnesterases with the anti-alzheimer drug rivastigmine[J].Biochemistry,2002,41(11):3 555-3 564.

二级参考文献21

  • 1郑彤,郭建友,朱霄鹏.老年痴呆症发病机制及其药物治疗[J].中国临床康复,2005,9(36):82-83. 被引量:30
  • 2曾秘,顾克敏,蒋英兰.阿尔茨海默病及治疗药物研究概况[J].中国药业,2006,15(6):59-61. 被引量:23
  • 3Lewczuk P, Esselmann H, Bibl M,et al. Tan protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease :original data and review of the literature [J]. Mol Neurosci, 2004 ; 23(2) :115-22.
  • 4Roger N, Rosenberg MD. Translational research on the way to effective therapy for Alzheimer disease [J]. Areh Gen Psychiatry, 2005 ;62 ( 11 ) : 1186-92.
  • 5Dodart JC, Mart RA. Gene delivery of human apolipoprotein E alters brain Aβ burden in a mouse model of Alzheimer's disease[J]. Proc Natl Acad Sci USA,2005;102(4) :1211-6.
  • 6De Simone R, Ramacci MT, Aloe L Effect of acetyl-L-camitine on forebrain cholinergic neurons of developing rats[J]. Int J Dev Neurosci, 1991 ;9 ( 1 ) :39-46.
  • 7Assunta I, Maria G, Orlando G. In vivo probing of the brain cholinergic system in the aged rat[J]. Ann NY Acad Sci,1991 ;621:90-7.
  • 8Ballard CG. Advances in the treatment of Alzheimer's disease :benefits of dual cholinesterase inhibition[ J]. Eur Neurol,2002 ;47:64-70.
  • 9Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease[J]. Biol Psychiatry,2001 ;49:279-88.
  • 10Wood MD, Murkitt KL. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry[J]. Br J Pharmacol Exp Ther, 1999 ; 290 ( 2 ) : 901-7.

共引文献52

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部